Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site

mAbs

Volumn 4, Issue 6, 2012, Pages 775-783

  List, Thomas ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Antibody; Biodistribution; Bispecific; Syngeneic; Tumor

Indexed keywords

BISPECIFIC ANTIBODY; CD3 ANTIGEN; FIBRONECTIN; HELXEDB ANTIBODY; IODINE 125; LYSOZYME; MCD3EXEDB ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONTROLLED STUDY; DNA SEQUENCE; DRUG DISTRIBUTION; DRUG TARGETING; FEMALE; ISOTOPE LABELING; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; T LYMPHOCYTE; TERATOCARCINOMA; TUMOR VOLUME;

ANTIBODY; BIODISTRIBUTION; BISPECIFIC; SYNGENEIC; TUMOR;

ALTERNATIVE SPLICING; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, CD3; ANTIGENS, NEOPLASM; EMBRYONAL CARCINOMA STEM CELLS; FIBRONECTINS; HUMANS; MICE; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANTIGEN, T-CELL; TERATOCARCINOMA;

EID: 84869798378     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.22271     Document Type: Article

References (49)

1. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314:628-31; PMID:2859527; http://dx.doi.org/10. 1038/314628a0
2. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985; 316:354-6; PMID:3160953; http://dx.doi.org/10.1038/316354a0
3. Stamova S, Feldmann A, Cartellieri M, Arndt C, Koristka S, Apel F, et al. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses. Anal Biochem 2012; 423:261-8; PMID:22274538; http://dx.doi.org/10.1016/j.ab.2011.12.042
4. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006; 43:763-71; PMID:16360021; http://dx.doi.org/10.1016/j.molimm.2005.03.007
5. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/ CD3-bispecific single-chain antibody construct. Int J Cancer 2005; 115:98-104; PMID:15688411; http://dx.doi.org/10.1002/ijc.20908
6. Schlereth B, Fichtner I, Lorenczewski G, Kleindienst P, Brischwein K, da Silva A, et al. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 2005; 65:2882-9; PMID:15805290; http://dx.doi.org/10.1158/0008-5472.CAN-04-2637
7. Weiner GJ, Hillstrom JR. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol 1991; 147:4035-44; PMID:1834746
8. Demanet C, Brissinck J, Van Mechelen M, Leo O, Thielemans K. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). J Immunol 1991; 147:1091-7; PMID:1830596
9. Demanet C, Brissinck J, Leo O, Moser M, Thielemans K. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma. Cancer Res 1994; 54:2973-8; PMID:8187084
10. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-7; PMID:18703743; http://dx.doi.org/10.1126/science. 1158545
11. Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-8; PMID:21576633; http://dx.doi.org/10.1200/JCO.2010.32.7270
12. Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983; 305:537-40; PMID:6137772; http://dx.doi.org/10.1038/305537a0
13. Holliger P, Prospero T, Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90:6444-8; PMID:8341653; http://dx.doi.org/10.1073/pnas.90.14.6444
14. Kontermann RE. Bispecific Antibodies. Springer Berlin, 2011
15. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002; 102:75-85; PMID:12353237; http://dx.doi.org/10.1002/ijc.10662
16. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res 1999; 59:347-52; PMID:9927045
17. Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 1999; 293:41-56; PMID:10512714; http://dx.doi.org/10.1006/jmbi.1999.3156
18. Kipriyanov SM. Generation of bispecific and tandem diabodies. Methods Mol Biol 2009; 562:177-93; PMID:19554296; http://dx.doi.org/10.1007/978-1-60327- 302-2-14
19. Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010; 36:458-67; PMID:20347527; http://dx.doi.org/10.1016/j. ctrv.2010.03.001
20. Nagorsen D, Kufer P, Zugmaier G, Baeuerle P. Dosage regimen for administering a CD19xCD3 bispecific antibody (Patent Nr.WO2011051307A1). In: WIPO/OMPI, ed., 2011
21. Cochlovius B, Kipriyanov SM, Stassar MJ, Schuhmacher J, Benner A, Moldenhauer G, et al. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. Cancer Res 2000; 60:4336-41; PMID:10969772
22. Shinkai Y, Koyasu S, Nakayama K, Murphy KM, Loh DY, Reinherz EL, et al. Restoration of T cell development in RAG-2-deficient mice by functional TCR transgenes. Science 1993; 259:822-5; PMID:8430336; http://dx.doi.org/10.1126/ science.8430336
23. Stork R, Campigna E, Robert B, Müller D, Kontermann RE. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem 2009; 284:25612-9; PMID:19628871; http://dx.doi.org/10. 1074/jbc.M109.027078
24. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, et al. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994; 59:612-8; PMID:7525495; http://dx.doi.org/10. 1002/ ijc.2910590507
25. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998; 273:21769-76; PMID:9705314; http://dx.doi.org/10.1074/ jbc.273.34.21769
26. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987; 6:2337-42; PMID:2822387
27. Fattorusso R, Pellecchia M, Viti F, Neri P, Neri D, Wüthrich K. NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis. Structure 1999; 7:381-90; PMID:10196121; http://dx.doi.org/10. 1016/S0969-2126(99)80051-3
28. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003; 9:571-9; PMID:12576420
29. Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009; 113:2265-74; PMID:19131554; http://dx.doi.org/10.1182/ blood-2008-06-160416
30. Erba PA, Sollini M, Orciuolo E, Traino C, Petrini M, Paganelli G, et al. Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med 2012; 53:922-7; PMID:22577235; http://dx.doi.org/10. 2967/jnumed.111.101006
31. Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012; 17:583-90; PMID:22289353; http://dx.doi.org/10.1016/j.drudis.2012.01.007
32. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005; 5:436-46; PMID:15928674; http://dx.doi.org/10.1038/nrc1627
33. Ebbinghaus C, Ronca R, Kaspar M, Grabulovski D, Berndt A, Kosmehl H, et al. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 2005; 116:304-13; PMID:15800913; http://dx.doi.org/10.1002/ ijc.20952
34. Melkko S, Halin C, Borsi L, Zardi L, Neri D. An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. Int J Radiat Oncol Biol Phys 2002; 54:1485-90; PMID:12459375; http://dx.doi.org/10.1016/S0360-3016(02)03927-5
35. Niesner U, Halin C, Lozzi L, Günthert M, Neri P, Wunderli-Allenspach H, et al. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 2002; 13:729-36; PMID:12121127; http://dx.doi.org/10.1021/bc025517+
36. Halin C, Niesner U, Villani ME, Zardi L, Neri D. Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. Int J Cancer 2002; 102:109-16; PMID:12385005; http://dx.doi.org/10.1002/ijc.10674
37. Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 2003; 63:3202-10; PMID:12810649
38. Gafner V, Trachsel E, Neri D. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer 2006; 119:2205-12; PMID:16823838; http://dx.doi.org/10.1002/ijc.22101
39. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 1987; 84:1374-8; PMID:2950524; http://dx.doi.org/10.1073/pnas.84.5.1374
40. Alegre ML, Tso JY, Sattar HA, Smith J, Desalle F, Cole M, et al. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J Immunol 1995; 155:1544-55; PMID:7636216
41. Amann M, Brischwein K, Lutterbuese P, Parr L, Petersen L, Lorenczewski G, et al. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Cancer Res 2008; 68:143-51; PMID:18172306; http://dx.doi. org/10.1158/0008-5472.CAN-07-2182
42. Schlereth B, Kleindienst P, Fichtner I, Lorenczewski G, Brischwein K, Lippold S, et al. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3. Cancer Immunol Immunother 2006; 55:785-96; PMID:16187083; http://dx.doi.org/10.1007/s00262-005-0082-x
43. Fiechter M, Frey K, Fugmann T, Kaufmann PA, Neri D. Comparative in vivo analysis of the atherosclerotic plaque targeting properties of eight human monoclonal antibodies. Atherosclerosis 2011; 214:325-30; PMID:21167484; http://dx.doi.org/10.1016/j.atherosclerosis.2010.11.027
44. Silacci M, Brack S, Schirru G, Mårlind J, Ettorre A, Merlo A, et al. Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 2005; 5:2340-50; PMID:15880779; http://dx.doi.org/10.1002/ pmic.200401273
45. Kim KS, Sun ZY, Wagner G, Reinherz EL. Heterodimeric CD3epsilongamma extracellular domain fragments: production, purification and structural analysis. J Mol Biol 2000; 302:899-916; PMID:10993731; http://dx.doi.org/10. 1006/jmbi.2000.4098
46. Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, et al. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999; 94:192-8; PMID:10381513
47. Demartis S, Tarli L, Borsi L, Zardi L, Neri D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 2001; 28:534-9; PMID:11357506; http://dx.doi.org/10.1007/s002590100480
48. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003; 102:4384-92; PMID:12933583; http://dx.doi.org/10.1182/blood-2003-04-1039
49. Bortoletto N, Scotet E, Myamoto Y, D'Oro U, Lanzavecchia A. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells. Eur J Immunol 2002; 32:3102-7; PMID:12385030; http://dx.doi. org/10.1002/1521- 4141(200211)32:11〈3102::AIDIMMU3102〉3.0.CO;2-C